We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Feedback Plc | FDBK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 60.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 60.50 | 60.50 | 60.50 | 60.50 | 60.50 |
| Industry Sector |
|---|
| ELECTRONIC & ELECTRICAL EQUIPMENT |
| Top Posts |
|---|
Posted at 10/7/2024 11:59 by ged5 Well that announcement contained a surprise for me but perhaps it shouldn't have done so."As part of the Agreement, Vertex will licence the database capabilities of Feedback's legacy picture archiving communication system Cadran PACS, now with the MedDream Viewer, which will allow it to build a PACS proposition that will initially be sold in South Africa and other international markets including the UK, where it sells PACS. This is another example of the Company's strategy to generate licencing royalties from its legacy products." I seem to remember FDBK saying they were moving away from PACS because of the growth opportunities and competition. Still, I guess they're only licencing the software. "Cadran is Feedback's established Picture Archiving and Communications System (PACS) which facilitates the review of medical imaging studies by clinicians. It is a progressive and rigorously tested Class 1 medical device with a longstanding legacy of service at NHS institutions, such as the Royal Papworth Hospital. However, it is currently positioned in a competitive market that shows little opportunity for future growth." 10th July 2019 Not really paying too much attention but I've only just noticed the description of FDBK:- Started out in 2021 as the specialist medical imaging technology company Became the specialist clinical communication company later in that year after the launch of Carelocker. The following year it became the frontline clinical technology company but went back to the specialist clinical communication company a few months later. In May 2023 it became the clinical infrastructure specialists and has stayed up to today. Been here on and off far too long considering it's a company not too sure of its direction. Probably keep a few just in case it does stumble onto something that will bring success. Anyone know what's happening with Axial 3d, Quest or CVS? |
Posted at 16/5/2024 13:21 by ducatiman They were going to reply after speaking to Fdbk. That tells you all you need to know. |
Posted at 10/4/2024 15:38 by ged5 Are you sure APH money isn't moving over here? With all the pilots FDBK has, there may be a flurry of take-offs. |
Posted at 10/4/2024 15:22 by blackhorse23 Money moving to APH [alliance pharma] , dividend announcement in 7 days |
Posted at 25/3/2024 12:01 by yump Ged5Yes but I think its a subset of what is being talked about as an EPR, which is a central digital record keeping system, which many hospitals appear to have already. Maybe I've got that wrong and Carelocker is a non-centralised alternative to a centralised EPR - non-centralised access is what is mentioned in the Carelocker blurb. In which case, we might have a "kerching" moment. It may be that FDBK have been able to get some traction because QVH are in the early stages of EPR planning and procurement (12mln worth over 7 years by the look of it). So FDBK are not coming to a trust with an add-on, where the trust has already set up their core EPR system. |
Posted at 25/3/2024 11:48 by ducatiman Fdbk rises on rumours of takeover bid by easyJet.Lol, Ged. Indeed a very welcome rise. Positive QVH news now and we should sail past £2. Surely it’s imminent? |
Posted at 19/3/2024 21:12 by yump Electronic patient records aren’t the same as what FDBK offers, which is an active pathway clinical management system although they clearly overlap in the area of checking patient records while on a pathway.Majority of trusts have epr. |
Posted at 05/3/2024 10:49 by ged5 This has been a good rise thanks imo to the hype going on on LSE. And don't forget this is only hype until some confirmation of contracts.We've heard for several years now that FDBK have great products and are welcomed by those clinicians that have used Bleepa but it is about time for contracts to be announced. I suspect end of March maybe April before contract news. Yesterday was a great time to top slice and with RSI so high today maybe the time for those who missed the opportunity. Will the rise continue or will there be a retrace? Place your bets! |
Posted at 04/3/2024 13:22 by ducatiman Yump, there are a number of pieces of good news that could be imminent.We could have 1 or multiples or of course as it’s Fdbk none. |
Posted at 03/3/2024 09:27 by ducatiman The stars are aligning LR2.Along with the huge cost saving for rural diagnosis, partnership with an Indian co’ and the desire to eradicate TB by 2025 one would hope that Fdbk can gain a substantial contract in India. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
